A 44-year-old man with chronic hepatitis C received three courses of interferon (IFN) therapy. HCVgenotype was lb, viral load was 1,200 kcopies/ml and interferon sensitivity determining region (ISDR) was the intermediate type before the 1st IFN therapy. The 1st and 2nd IFN therapies resulted in failure to yield a sustained response. Seven years after from the 1st therapy, viral load had decreased to 15 kcopies/ml and ISDR had changed to mutant type. The 3rd IFN therapy yielded sustained response. Thus, we should consider retreatment with IFNwhena decrease of the viral load and change of ISDRto mutant type are observed. (Internal Medicine 40: 489-492, 2001) 
Introduction
Hepatitis C virus (HCV)is an enveloped positive stranded RNAvirus which preferentially replicates in hepatocytes (1 , 2) . HCVinfection often progresses to chronic hepatitis, cirrhosis and hepatocellular carcinoma (3, 4). Interferon (IFN) has been shown to be efficacious for chronic hepatitis C (5-7). The mutations in interferon sensitivity determining region (ISDR: aa2209-2248) in the nonstructural protein 5Ahave been reported to correlate with response to IFN therapy in genotype-Ib-infected patients (8-12). HCVwith mutant ISDR[isolates with 4 or more amino acid substitutions compared with HCV-J(13)] are responsive whereas those with wild ISDR (isolates with HCV-J sequence) or intermediate ISDR (isolates with 1 to 3 substitutions) are resistant to IFN therapy. It was also reported that the viral load of the patients with mutant ISDR was significantly smaller than that in patients with wild or intermediate ISDR (9-1 1). Here, we report a patient with chronic hepatitis C whoobtained a sustained response with the 3rd IFN therapy after a decrease of viral load and mutation of ISDR from intermediate type to mutant type.
Case Report
A 44-year-old man who had been followed up for chronic hepatitis C since 1987 started to receive the 1st IFN therapy on March 4, 1991. He had no history of alcohol abuse or blood transfusion. A physical examination showed no remarkable abnormalities. Blood laboratory tests showed that he was positive for anti-HCV antibody (second generation enzyme immunoassay; Abbott Laboratories, North Chicago, IL) and was negative for hepatitis B virus marker. Viral load was 1 ,200 kcopies/ ml by Amplicor HCVMonitor test (Nippon Roche Inc., Tokyo) and genotype was lb by Okamoto's method (14) ( 
